Haematology 2018

PD1/PD-L1 in DLBCL

• Investigation of nivolumab (anti PD-1), pembrolizumab (anti PD-1), avelumab (PD- 1), durvalumab (anti PD-L1) and atezoluimumab (PD-L1) in DLBCL • PD-L1 expressed on about 10-30% of patients with DLBCL (more frequent in PMBL) • High is EBV +ve DLBCL and TCRLCL (Chen et al. Clin Canc Res 2013) • Nivoulumab ORR DLBCL 36% (n=11) median duration of response 22 weeks (Lesokhin et al. ASH 2014) • Waiting for combination data…

(Chen et al. Clin Canc Res 2013)